Abstract:BACKGROUND:Immunotherapy targeting programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) has been shown to be effective in a variety of malignancies but has poor efficacy in pancreatic ductal adenocarcinoma (PDAC). Studies have shown that PD-L1 expression in tumors is an important indicator of the efficacy of immunotherapy. Tumor cells usually evade chemotherapy and host immune surveillance by epigenetic changes. Protein arginine methylation is a common posttranslational modification. Protein arginine methyltransferase (PRMT) 1 is deregulated in a wide variety of cancer types, whose biological role in tumor immunity is undefined. AIM:To investigate the combined effects and underlying mechanisms of anti-PD-L1 and type I PRMT inhibitor in pancreatic cancer in vivo. METHODS:PT1001B is a novel type I PRMT inhibitor with strong activity and good selectivity. A mouse model of subcutaneous Panc02-derived tumors was used to evaluate drug efficacy, toxic and side effects, and tumor growth in vivo. By flow cytometry, we determined the expression of key immune checkpoint proteins, detected the apoptosis in tumor tissues, and analyzed the immune cells. Immunohistochemistry staining for cellular proliferation-associated nuclear protein Ki67, TUNEL assay, and PRMT1/PD-L1 immunofluorescence were used to elucidate the underlying molecular mechanism of the antitumor effect. RESULTS:Cultured Panc02 cells did not express PD-L1 in vitro, but tumor cells derived from Panc02 transplanted tumors expressed PD-L1. The therapeutic efficacy of anti-PD-L1 mAb was significantly enhanced by the addition of PT1001B as measured by tumor volume (1054.00 ± 61.37 mm3 vs 555.80 ± 74.42 mm3, P < 0.01) and tumor weight (0.83 ± 0.06 g vs 0.38 ± 0.02 g, P < 0.05). PT1001B improved antitumor immunity by inhibiting PD-L1 expression on tumor cells (32.74% ± 5.89% vs 17.95% ± 1.92%, P < 0.05). The combination therapy upregulated tumor-infiltrating CD8+ T lymphocytes (23.75% ± 3.20% vs 73.34% ± 4.35%, P < 0.01) and decreased PD-1+ leukocytes (35.77% ± 3.30% vs 6.48% ± 1.08%, P < 0.001) in tumor tissue compared to the control. In addition, PT1001B amplified the inhibitory effect of anti-PD-L1 on tumor cell proliferation and enhanced the induction of tumor cell apoptosis. PRMT1 downregulation was correlated with PD-L1 downregulation. CONCLUSION:PT1001B enhances antitumor immunity and combining it with anti-PD-L1 checkpoint inhibitors provides a potential strategy to overcome anti-PD-L1 resistance in PDAC.

Midazolam Exhibits Antitumour and Anti-Inflammatory Effects in a Mouse Model of Pancreatic Ductal Adenocarcinoma

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma

Effect of 5-Lox/cox-2 Common Inhibitor Dhdmbf30 on Pancreatic Cancer Cell Capan2

Inhibition Of Cancer Cell Proliferation By Midazolam By Targeting Transient Receptor Potential Melastatin 7

Effects of Tramadol Via a Μ-Opioid Receptor on Pancreatic Ductal Adenocarcinoma in Vitro and in Vivo.

Inhibition of P21 Activated Kinase Enhances Tumour Immune Response and Sensitizes Pancreatic Cancer to Gemcitabine

In Vitro and In Vivo Effects of Melatonin-Containing Combinations in Human Pancreatic Ductal Adenocarcinoma

Effects of Midazolam Combined with Sufentanil on Injury and Expression of HMGB1 and NF-κB in Rats with Pancreatitis.

The Protection of Midazolam Against Immune Mediated Liver Injury Induced by Lipopolysaccharide and Galactosamine in Mice

Duloxetine Improves Cancer-Associated Pain in a Mouse Model of Pancreatic Cancer Through Stimulation of Noradrenaline Pathway and Its Antitumor Effects

Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis

Orthotopic Inflammation-Related Pancreatic Carcinogenesis in A Wild-Type Mouse Induced by Combined Application of Caerulein and Dimethylbenzanthracene

Combination Doxorubicin And Interferon-Alpha Therapy Stimulates Immunogenicity Of Murine Pancreatic Cancer Panc02 Cells Via Up-Regulation Of Nkg2d Ligands And Mhc Class I

Dimethylaminomicheliolide (DMAMCL) Inhibits Cell Proliferation and Increases Apoptosis and Efficacy of Gemcitabine via Annexin A2 in Pancreatic Adenocarcinoma

Mirogabalin improves cancer-associated pain but increases the risk of malignancy in mice with pancreatic cancer

Novel Therapeutic Strategy to Inhibit Growth of Pancreatic Cancer Organoids Using a Rational Combination of Drugs to Induce Mitotic Arrest and Apoptosis.

Midostaurin Modulates Tumor Microenvironment and Enhances Efficacy of Anti-PD-1 against Colon Cancer

Efficacy of Tumor-Targeting Salmonella Typhimurium A1-R in Combination with Anti-Angiogenesis Therapy on A Pancreatic Cancer Patient-Derived Orthotopic Xenograft (pdox) and Cell-Line Mouse Models

Patient Derived Xenografts Demonstrate the Radiosensitizing Effect of Inhibiting MAPK Signaling Pathway in Pancreatic Ductal Adenocarcinoma

Dexmedetomidine Provides Type-Specific Tumour Suppression Without Tumour-Enhancing Effects in Syngeneic Murine Models.

Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.